107 related articles for article (PubMed ID: 8279774)
1. The role of lonidamine in the treatment of breast cancer patients.
Rosso R; Gardin G; Pronzato P; Camoriano A; Merlini L; Naso C; Rosso M; Barone C; Nascimben O; Ianniello G
Ann N Y Acad Sci; 1993 Nov; 698():349-56. PubMed ID: 8279774
[No Abstract] [Full Text] [Related]
2. Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study.
Gardin G; Barone C; Nascimben O; Ianniello G; Sturba F; Contu A; Pronzato P; Rosso R
Eur J Cancer; 1996 Jan; 32A(1):176-7. PubMed ID: 8695230
[No Abstract] [Full Text] [Related]
3. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
4. Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide.
Berruti A; Tampellini M; Gorzegno G; Dogliotti L
Chest; 1997 May; 111(5):1473-4. PubMed ID: 9149629
[No Abstract] [Full Text] [Related]
5. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Santangelo M; Bucci L; Fei L; Di Martino N; Mantovani G; Caponigro F
Breast Cancer Res Treat; 1995 Sep; 35(3):243-8. PubMed ID: 7579494
[TBL] [Abstract][Full Text] [Related]
7. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Nisticò C; Garufi C; Milella M; D'Ottavio AM; Vaccaro A; Fabi A; Terzoli E
Breast Cancer Res Treat; 1999 Aug; 56(3):233-7. PubMed ID: 10573114
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
[TBL] [Abstract][Full Text] [Related]
10. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
12. Combination of epirubicin and lonidamine for treatment of advanced breast cancer.
Moraglio L; Brema F; Pastorino G; Martini MC; Vallauri M
Tumori; 1995; 81(2):107-11. PubMed ID: 7778213
[TBL] [Abstract][Full Text] [Related]
13. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
14. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
15. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
16. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Papaldo P; Ferretti G; Di Cosimo S; Giannarelli D; Marolla P; Lopez M; Cortesi E; Antimi M; Terzoli E; Carlini P; Vici P; Botti C; Di Lauro L; Naso G; Nisticò C; Mottolese M; Di Filippo F; Ruggeri EM; Ceribelli A; Cognetti F
J Clin Oncol; 2006 Jul; 24(19):3048-55. PubMed ID: 16769988
[TBL] [Abstract][Full Text] [Related]
17. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
Marschner N; Kreienberg R; Souchon R; Räth U; Eggeling B; Voigtmann R; Ruffert K; Schütte M; Ammon A; Kesztyüs T
Semin Oncol; 1994 Feb; 21(1 Suppl 1):10-6. PubMed ID: 8153652
[No Abstract] [Full Text] [Related]
20. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
